Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: Reduced awakening from sleep during hypoglycemia

Diabetes

Volumn 52, Issue 5, 2003, Pages 1195-1203

  Banarer, Salomon ^b   Cryer, Philip E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; GLUCAGON; NORADRENALIN; PANCREAS POLYPEPTIDE;

ADULT; AROUSAL; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; SLEEP;

BLOOD GLUCOSE; C-PEPTIDE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; HUMANS; HYPOGLYCEMIA; INSULIN; REFERENCE VALUES; SLEEP; SLEEP STAGES; SLEEP, REM; WAKEFULNESS;

EID: 0242516067     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.5.1195     Document Type: Article

References (27)

1. Cryer PE: Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 45:937-948, 2002
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
3. The United Kingdom Prospective Diabetes Study Group: Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998
4. Dagogo-Jack SE, Craft S, Cryer PE: Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus: recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 91:819-828, 1993
5. Segel SA, Paramore DS, Cryer PE: Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 51:724-733, 2002
6. Cryer PE: Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol 281:E1115-E121, 2001
7. The Diabetes Control and Complications Control Research Group: Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 90:450-459, 1991
8. The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286, 1997
9. Bendtson I, Rosenfalck AM, Binder C: Nocturnal versus diurnal hormonal counterregulation to hypoglycemia in type 1 (insulin-dependent) diabetes patients. Acta Endocrinol 128:109-115, 1993
10. Jones TW, Porter P, Sherwin RS, Davis EA, O'Leary P, Frazer F, Byrne G, Stick S, Tamborlane WV: Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 338:1657-1662, 1998
11. Schwartz NS, Clutter WE, Shah SD, Cryer PE: The glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 79:777-781, 1987
12. Towler DA, Havlin CE, Craft S, Cryer P: Mechanisms of awareness of hypoglycemia: perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 42:1791-1798, 1993
13. Rechtschaffen A, Kales A (Eds.): A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages in Human Subjects. Los Angeles,: UCLA Brain Information Service/Brain Research Institute, 1968
14. Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH: Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes 26:22-29, 1977
15. Ensinck J: Immunoassays for glucagon. In Handbook of Experimental Pharmacology. Vol 66. Lefebrve P, Ed. New York, Springer Verlag, 1983, p. 203-221
16. Gingerich RL, Lacy PE, Chance RE, Johnson MG: Regional pancreatic concentration and in-vitro secretion of canine pancreatic polypeptide, insulin, and glucagon. Diabetes 27:96-101, 1978
17. Schalch D, Parker M: A sensitive double antibody radioimmunoassay for growth hormone in plasma. Nature 703:1141-1142, 1964
18. Farmer RW, Pierce CE: Plasma cortisol determination: radioimmunoassay and competitive protein binding compared. Clin Chem 20:411-414, 1974
19. Shah SD, Clutter WE, Cryer PE: External and internal standards in the single-isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine. J Lab Clin Med 106:624-629, 1985
20. Hosaka K, Kijucki T, Mitsuhida N, Kawaguchi A: A new colorimetric method for the determination of free fatty acids with acyl-CoA synthetase and acyl-CoA oxidase. J Biochem (Tokyo) 89:1799-1803, 1981
21. Pinter J, Hayaski J, Watson J: Enzymatic assay of glycerol, dihydroxyacetone and glyceraldehyde. Arch Biochem Biophys 121:404-414, 1967
22. Lowry O, Passoneau J, Hasselberger F, Schultz D: Effect of ischemia on known substrates and co-factors of the glycolytic pathway of the brain. J Biol Chem 239:18-30, 1964
23. Cahill GF Jr, Herrera MG, Morgan AP, Soeldner JS, Steinke J, Levy PL, Reichard GA Jr, Kipnis DM: Hormone-fuel interrelationships during fasting. J Clin Invest 45:1751-1769, 1966
24. Perriello G, DeFeo P, Torlone E, Fanelli C, Santuesanio F, Brunetti P, Bolli GB: The dawn phenomenon in type 1 (insulin dependent) diabetes mellitus: magnitude, frequency, variability and dependence on glucose counterregulation and insulin sensitivity. Diabetes 34:21-28, 1991
25. Davis SN, Shavers C, Costa F, Mosqueda-Garcia R: Role of cortisol in the pathogenesis of deficient counterregulation after antecedent hypoglycemia in normal humans. J Clin Invest 98:680-691, 1996
26. Davis SN, Shavers C, Davis B, Costa F: Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses. J Clin Invest 100:429-438, 1997
27. Fanelli CG, Paramore DS, Hershey T, Terkamp C, Ovalle F, Craft S, Cryer PE: Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes mellitus. Diabetes 47:1920-1927, 1998